In 2025, a doctor at one Toronto hospital steered a robot through the blood vessels of a patient at another hospital across the city. The company behind that robot now has to prove to American regulators that it is safe enough for everyday care.
That company is Remedy Robotics. On November 16, 2026, the San Francisco start-up announced a $62 million Series B led by DCVC.
A Series B is a company’s second major round of outside funding, usually raised once the product has been shown to work. Each later letter means a bigger round, like the one in Fractile’s £577 million Series C.
Three new investors came in: UC Investments, which manages the University of California’s money; Skip Capital; and Hostplus, an Australian pension fund. Earlier backers came back too, including Blackbird, KdT Ventures, Divergent Capital and Build Collective, the firm run by Tony Fadell, who helped create the iPod and later founded Nest.
The robot called N1
Remedy’s product is the N1 system. It works on endovascular procedures, which are treatments done from inside the blood vessels. A doctor threads thin wires and catheters in through an artery instead of opening the body.
Before a case, the N1 uses machine learning to study the patient’s scans and rehearse the procedure. During the case, it lines up the 3D scan with the live 2D X-ray so the operator can see where the tools are. The same machine can be run from the room, from another building, or on its own.
Remedy wants to use it for brain, heart and other blood vessel cases. But Remedy Robotics lists the N1 as investigational. It can’t be sold or used on patients outside a study anywhere in the world yet.
Two firsts in Toronto
The first big test came in 2024. In a first-in-human study at St Michael’s Hospital in Toronto, led by Dr. Vitor Mendes Pereira, the robot did neurointerventional procedures entirely on its own hardware. Neurointerventional means treating blood vessels in the brain.
The bigger moment came in 2025. This time the controls were at one hospital and the patient was at another, with St Joseph’s Health Centre and St Michael’s on either end. Remedy calls these the world’s first fully remote neurointerventional procedures.
CEO and co-founder Dr. David Bell has argued for years that a stroke patient’s chances shouldn’t depend on which hospital the ambulance reaches. In the company’s announcement, Remedy says only 2.8 percent of stroke patients worldwide who could get this kind of treatment actually get it.
Most hospitals don’t have a specialist on call who can do it. A robot that a specialist can drive from far away is Remedy’s answer to that shortage.
When the remote cases went public in October 2025, Remedy also revealed it had raised $35 million across its seed and Series A rounds. Axios reported then that the company was in talks to raise about $50 million for a Series B. The round it closed came in $12 million above that.
The decision to fund a pivotal trial
Bell and CTO and co-founder Jake Sganga have made a clear choice about the money. Most of it goes toward a pivotal trial across the University of California’s hospitals.
A pivotal trial is the large study a device maker runs to give the FDA the evidence it needs to approve a product. Remedy is aiming first for approval in neurovascular cases.
Some deep-tech start-ups put a big round into building things, the way Biomatter put its Series A into a lab of its own. Remedy is putting most of its money into proving the robot works.
The rest goes into prototype N1 units for clinical partners, including SVIN Mission Thrombectomy, which names Remedy as its only robotics partner, and the Australian Stroke Alliance. Work on the AI and the robot’s autonomous features continues.
Hold on, the university is paying in and hosting the trial?
Yes. And it isn’t a new relationship.
Remedy has worked with University of California doctors since 2021. Those doctors know the robot better than most investors. Now the university’s investment office owns part of the company, and the university’s hospitals will run the study that decides whether the robot reaches regular patients.
That doesn’t predict how the trial will go. It does show that people who have watched the N1 up close for five years wanted money in it.
What the FDA will want to see
Remedy hasn’t given a start date for the UC trial or a timeline for an FDA filing. Until regulators approve it, the N1 stays a research device, and stroke patients outside a study can’t be treated with it.
